Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07145229 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare

A Phase 2 study of Gout Flare and Acute Gouty Arthritis, sponsored by Atom Therapeutics Co..

Recruiting
Registry status
Phase 2
Development phase
380
Enrollment target
20
Study locations

NCT07145229 is a Phase 2 study of Gout Flare and Acute Gouty Arthritis that is actively recruiting participants, run by Atom Therapeutics Co.. The registered enrollment target is 380 participants, below the 726-participant average among 5 other Gout Flare trials with a reported enrollment target (48% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07145229, a Phase 2 study of Gout Flare and Acute Gouty Arthritis, is actively recruiting participants, sponsored by Atom Therapeutics Co..

RECRUITING
Registry status
Phase 2
Development phase
380 participants
Enrollment target
20
Study locations

Study Summary

A randomized, double-blind, international multicenter, colchicine and placebo-controlled study to evaluate the efficacy and safety of ABP-745 in subjects with acute gout. Efficacy of ABP-745 in reducing pain and swelling compared with standard colchicine treatment and placebo will be evaluated in participants with acute gout. The primary efficacy measurement will be pain score after treatment.

Conditions Studied

Gout Flare Acute Gouty Arthritis Acute Gout Flare Gout Flares

Interventions

  • DRUG Placebo
  • DRUG Colchicine
  • DRUG ABP-745 Dose A
  • DRUG ABP-745 Dose B

Study Locations (20)

New South Wales

  • Emeritus Sydney - Botany
  • Canopy Clinical Research Northern Beaches - Brookvale
  • Novatrials - Kotara
  • Genesis Research Services - Newcastle

Louisiana

  • Northshore Research Associates - Alexandria
  • DelRicht Research - Baton Rouge
  • DelRicht Research - New Orleans

Victoria

  • Emeritus Melbourne - Camberwell
  • Canopy Clinical Research Altona North - North Altona

Arizona

  • Onyx Clinical Research - Peoria

California

  • Exinia Research - La Mesa

Georgia

  • Evergreen Clinical Trial - Norcross

Illinois

  • Bioluminux Clinical Research - Naperville

Iowa

  • Exinia Research - Des Moines

Trial Details

FieldValue
Enrollment Target 380 participants
Start Date 2025-08-26
Est. Completion 2026-06
Phase Phase 2

Sponsor

Atom Therapeutics Co.

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07145229

The ClinicalTrials.gov registry entry for NCT07145229 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 380 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 726-participant average among 5 other Gout Flare trials with a reported enrollment target (48% lower). The listed sponsor is Atom Therapeutics Co., which has 9 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Gout Flare appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT07145229 reports 20 study locations spanning 14 distinct geographic areas - top geographies include New South Wales, Louisiana, Victoria.

Frequently Asked Questions

What is clinical trial NCT07145229 about?

NCT07145229 is a clinical study titled "Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare". A randomized, double-blind, international multicenter, colchicine and placebo-controlled study to evaluate the efficacy and safety of ABP-745 in subjects with acute gout. Efficacy of ABP-745 in reducing pain and swelling compared with standard colchicine treatment and placebo will be evaluated in pa...

What is the current status of trial NCT07145229?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 380 participants. The study started on 2025-08-26. Estimated completion is 2026-06.

What conditions does trial NCT07145229 study?

This clinical trial studies the following conditions: Gout Flare, Acute Gouty Arthritis, Acute Gout Flare, Gout Flares.

What interventions are being tested in trial NCT07145229?

The interventions under investigation include: Placebo (DRUG), Colchicine (DRUG), ABP-745 Dose A (DRUG), ABP-745 Dose B (DRUG).

Who is sponsoring clinical trial NCT07145229?

This trial is sponsored by Atom Therapeutics Co., which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07145229 being conducted?

This trial has 20 study locations across Arizona, California, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gout Flare

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gout Flare

All registered trials for this condition

Acute Gouty Arthritis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.